细胞治疗的共同研究及授权契约:2016年～2025年

"细胞疗法合作与许可交易" 报告提供了前所未有的途径，让我们能够全面了解全球领先生物製药公司签署的细胞疗法交易。

本报告详细介绍了2016年至2025年的细胞疗法交易，并详细分析了企业达成细胞疗法交易的方式和原因。这些交易通常包含多个环节，从合作研发到成果商业化。

本报告涵盖合作、开发、研究和授权交易，并包含自2016年以来宣布的989项细胞疗法交易的完整清单。此外，报告还包含本公司及其合作伙伴向美国证券交易委员会提交的合约文件（如有）。

本报告的第一章介绍了细胞疗法交易。

第一章是对报告的介绍。

第2章概述了自2016年以来的细胞疗法交易活动。

第3章概述了自2016年以来的主要细胞疗法交易。交易按总价值列出。

第4章列出了在细胞疗法交易中最活跃的25家公司，随后进行了简要总结，并提供了完整的细胞疗法交易清单和公开的合约文件。

第5章全面深入地回顾了自2016年1月以来已完成和宣布的细胞疗法交易，重点介绍了已公开合约文件的交易。

第6章全面深入地回顾了自2016年1月以来已完成和宣布的细胞疗法合作计画。本章按感兴趣的特定细胞疗法技术类型进行组织。

该报告还包含大量图表和数据，展现了自2016年以来细胞疗法交易活动和趋势。

此外，综合交易目录依公司A-Z、交易类型及治疗目标进行整理。每个交易标题都透过网页连结连结到线上交易记录，并在可用的地方包含合约文件，方便您随时存取每份协议文件。

主要的优点

"细胞疗法合作与授权协议" 一书提供读者以下主要优势：

• 了解自2016年以来的交易趋势
• 浏览细胞疗法合作与许可交易
• 基准分析 - 确定交易的市场价值
• 财务条款 - 一次性付款、里程碑付款、特许权使用费
• 依公司A-Z、交易类型及治疗领域排序的交易目录
• 依交易价值排序的主要交易
• 最活跃的交易撮合者
• 确定每笔交易的资产和交易条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款是否适合您的合作公司
• 节省数百小时的研究时间

研究范围

• 细胞疗法 "合作与许可交易" 旨在深入了解全球领先生物製药公司达成的细胞疗法趋势和交易结构。

细胞疗法合作与许可交易包括：

• 生物製药产业的细胞疗法交易趋势
• 涵盖製药和生物技术领域的细胞疗法交易记录目录
• 主要细胞疗法交易
• 最活跃的细胞疗法许可交易撮合者
• "细胞疗法合作与许可交易" 提供全面的交易记录存取权限，包括合约文件。

分析合约文件有助于进行以下方面的尽职调查：

• 授予或选择的具体权利是什么？
• 实际授予合约伙伴什么？
• 授予了哪些独家权利？
• 合约的付款结构是怎样的？
• 销售和付款如何审计？
• 合约期限是多久？
• 合约的关键条款如何界定？
• 知识产权如何处理归属于谁？
• 谁负责商业化？
• 谁负责开发、供应和製造？
• 如何管理保密和资讯揭露？
• 如何解决争议？
• 合约在什么情况下可以终止？
• 如果所有权发生变更会怎样？
• 双方约定了哪些分授权和分包条款？
• 公司坚持哪些标准条款？
• 哪些标准条款在不同合作伙伴或不同交易类型之间似乎有所不同？
• 公司在契约法方面主张哪些管辖权？

目录

摘要整理

第1章 简介

第2章 细胞治疗交易趋势

• 简介
• 多年的细胞治疗交易
• 最活跃的细胞治疗交易业者
• 细胞治疗交易，各交易类型
• 细胞治疗交易，各治疗领域
• 细胞治疗交易，各业界
• 细胞治疗交易的交易条件
  • 细胞治疗交易的主要金额
  • 细胞治疗契约的预付款金
  • 细胞治疗契约的里程金
  • 细胞治疗的特许权率

第3章 -主要细胞治疗交易

• 简介
• 主要的细胞治疗交易，各金额

第4章 -最活跃的细胞治疗交易业者

• 简介
• 最活跃的细胞治疗交易业者
• 最活跃的细胞治疗交易的企业简介

第5章 细胞治疗契约交易名录

• 简介
• 细胞治疗契约交易名录

第6章 各技术类型的细胞治疗交易

• 交易名录
• 交易名录- 细胞治疗交易(AZ)，公司
• 交易名录- 细胞治疗交易，各交易类型
• 交易名录- 细胞治疗交易，各治疗领域
• 交易类型定义
• 关于调查公司
• 目前共同研究
• 目前契约
• 最近的报告标题

Cell Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cell therapy deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of cell therapy deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter cell therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 989 cell therapy deals announced since 2016 including financial terms where available including links to online deal records of actual cell therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cell therapy dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cell therapy dealmaking since 2016.

Chapter 3 provides an overview of the leading cell therapy deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cell therapy dealmaking with a brief summary followed by a comprehensive listing of cell therapy deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of cell therapy deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of cell therapy partnering deals signed and announced since Jan 2016. The chapter is organized by specific cell therapy technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in cell therapy deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cell Therapy Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse cell therapy collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Cell Therapy Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cell therapy trends and structure of deals entered into by leading biopharma companies worldwide.

Cell Therapy Collaboration and Licensing Deals includes:

• Trends in cell therapy dealmaking in the biopharma industry
• Directory of cell therapy deal records covering pharmaceutical and biotechnology
• The leading cell therapy deals by value
• Most active cell therapy licensing dealmakers
• Cell Therapy Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cell therapy dealmaking

• 2.1. Introduction
• 2.2. Cell therapy deals over the years
• 2.3. Most active cell therapy dealmakers
• 2.4. Cell therapy deals by deal type
• 2.5. Cell therapy deals by therapy area
• 2.6. Cell therapy deals by industry sector
• 2.7. Deal terms for cell therapy deals
  • 2.7.1 Cell therapy deals headline values
  • 2.7.2 Cell therapy deal upfront payments
  • 2.7.3 Cell therapy deal milestone payments
  • 2.7.4 Cell therapy royalty rates

Chapter 3 - Leading cell therapy deals

• 3.1. Introduction
• 3.2. Top cell therapy deals by value

Chapter 4 - Most active cell therapy dealmakers

• 4.1. Introduction
• 4.2. Most active cell therapy dealmakers
• 4.3. Most active cell therapy deals company profiles

Chapter 5 - Cell therapy contracts dealmaking directory

• 5.1. Introduction
• 5.2. Cell therapy contracts dealmaking directory

Chapter 6 - Cell therapy dealmaking by technology type

• Deal directory
• Deal directory - Cell therapy deals by company A-Z
• Deal directory - Cell therapy deals by deal type
• Deal directory - Cell therapy deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Cell therapy deals since 2016
• Figure 2: Active cell therapy dealmaking activity - 2016 - 2025
• Figure 3: Cell therapy deals by deal type since 2016
• Figure 4: Cell therapy deals by therapy area since 2016
• Figure 5: Cell therapy deals by industry sector since 2016
• Figure 6: Cell therapy deals with a headline value
• Figure 7: Cell therapy deals with an upfront value
• Figure 8: Cell therapy deals with a milestone value
• Figure 9: Cell therapy deals with a royalty rate value
• Figure 10: Top cell therapy deals by value since 2016
• Figure 11: Most active cell therapy dealmakers 2016 - 2025
• Figure 12: Cell therapy deals by technology type since 2016